Journal
LANCET
Volume 388, Issue 10061, Pages 2796-2810Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30512-8
Keywords
-
Categories
Funding
- Theralase
- Sanofi
- Taris
- Spectrum Pharmaceuticals
- MDxHealth
- Heat Biologics
- Photocure
- Telesta Therapeutics
- Merck
- Abbott Molecular
- FKD
- Pacific Edge
- BioCancell
- Vaxxion
- UroGen
- Telesta
- Sitka
- Neucleixx
- Bladder Cancer Journal
- Ferring
- ENDO Pharmaceuticals
- Viventia
- Roche/Genentech
- Genome DX
- Abbott
- Cepheid
Ask authors/readers for more resources
Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available